



ACN 103 782 378

28 February 2022

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

Attention: Barbara Lim
By email only: barbara.lim@asx.com.au

Dear Madam,

SECTION 708A CLEANSING NOTICE

This notice is given by Zelira Therapeutics Ltd (**Zelira or the Company**) (ASX: ZLD) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

1. On 28 February 2022, the Company issued 21,029,386 Shares to Class A Performance Right holders following the conversion of Performance Rights pursuant to the satisfaction of the Class A Performance Right milestone as announced on 10 January 2022; and
2. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
3. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
4. As at the date of this notice Zelira Therapeutics has complied with:
 - a. The provisions of Chapter 2M of the Corporations Act as they apply to Company; and
 - b. Section 674 of the Corporations Act; and
5. As at the date of this notice, there is no information that is “excluded information” (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by Zelira.

Please see the attached Appendix 2A for details of the share issue.

This announcement has been authorized by the Board of the Company.

Yours sincerely

Tim Slate
Company Secretary

